Catalyst Pharmaceuticals Inc CPRX shares are trading lower by 1.47% at $10.71. Traders and investors are watching for the company’s second-quarter earnings report, confirmed for Tuesday’s after-hours session.
According to analyst consensus estimates, Catalyst Pharmaceuticals is expected to report EPS of 17 cents on revenue of $49.21 million. The company last quarter missed EPS estimates by 14.29% and exceeded revenue estimates by 0.79% respectively.
According to data from Benzinga Pro, Catalyst Pharmaceuticals has a 52-week high of $11.32 and a 52-week low of $4.81.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.